Tricyclic antidepressants effective for headaches, but comparative trials would be more convincing
This article was originally published in Scrip
Tricyclic antidepressants have been used for treating headaches as an unlicensed indication since the 1960s (as well as being recommended for this in European and US neurology clinical guidelines), but their role was given a further boost in a meta-analysis study published in the BMJ last week. Despite evidence from the meta-analysis that tricyclics are effective preventative treatments for headache and migraine, the real clinical proof of their effectiveness is unlikely to be generated by the pharmaceutical industry, commentators says.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.